Weight-loss drug linked to sleep apnea reduction: Research

The weight-loss drug Zepbound was linked to a reduction in obstructive sleep apnea (OSA), according to new research. 

Pharmaceutical manufacturer Eli Lilly on Wednesday said injections of its obesity drug tirzepatide — commonly known as Zepbound — “significantly reduced” the number of sleep apnea events during one’s sleep when compared to a placebo.

Sleep apnea is a sleep disorder that causes one’s breathing to repeatedly stop and start. The disorder can cause daytime exhaustion...